Latest From Tripex Pharmaceuticals
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.
Biopharma financing totaled $9.7 billion, almost half from follow-on public offerings; there was big consolidation in the generics and health services industries. AstraZeneca signed a dozen partnerships, many of which focused on oncology.
- Therapeutic Areas
- Respiratory, Pulmonary
- Parent & Subsidiaries
- Tripex Pharmaceuticals
- Senior Management
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.